CD274 and neoplasm: Recent researches have indicated that the expression of PD-L1 (Herbst et al. 2014), tumor mutation load (TMB) (Rizvi et al. 2018), special gene mutation, tumor-infiltrating lymphocytes (TIL) (Lu et al. 2019), antigen presentation defects (Thompson et al. 2021), gene expression profiles (GEPs) (Wang et al. 2019) could be used as predictive biomarkers of immunotherapy efficacy.